Abstract
Introduction: breast cancer is the most common cancer in women. More than one million women are affected by this disease worldwide. Estrogen receptor (ER), progesterone receptor (PR) and Her-2 (Human Epidermal growth factor receptor) analysis have been accepted as established procedures in the routine management of patients with breast cancer.
Aim of our study is to to evaluate the estrogen receptor (ER), progesterone receptor (PR) and Her-2 expression in breast carcinomas by immunohistochemistry and clinicopathological parameters like patient’s age, histological grade in the patients registered in our institute between 2010 to 2014.
Methods: retrospective study of 78 female invasive breast carcinomas registered in our Institute from January 2010 to Dec 2014.
Results: the age of the patients ranged from 24 to 80 years, with a mean of 48.5, and the majority of the tumors were T2 invasive ductal carcinoma. Triple-negative breast cancers constituted 25 % of our cases and were most commonly grade 2. So we conclude that our group has a smaller number of patients but generally the hormonal receptor expression appears to be lower in our group of patients compared to the West. Further larger size studies are needed for better evaluation.
Keywords: Breast, triple negative.
References
- Dumitrescu RG, Cotarla I. Understanding breast cancer risk-where do we stand in 2005? J Cell Mol Med 2005;9:208-21.
- Rastelli F, Crispino S. Factors predictive of response to hormone therapy in breast Tumori 2008;94:370-83.
- Pesic I, Krstic M, Pavlovic M, Ilic D, Dimitrios K. Hormone sensitivity in women with breast cancer. Acta Medica Medianae 2007;46:25-30
- Murthy NS, Chaudhry K, Nadayil D, Agarwal UK, Saxena S. Changing trends in incidence of breast cancer: Indian scenario. Indian J Cancer 2009;46:73-4.
- Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Hormone receptors do not predict the Her2/neu status in all age groups of women with an operable breast cancer. Ann Oncol 2005;16:1755-65.
- Koffi B, Sepou A, Doui D, Goumba C, Djabanga S. Epidemiological and histological characteristics of breast cancers in Bangui. Méd Afr Noire. 2004; 51:112–4.
- Li T, Mello-Thoms C, Brennan PC. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence. Brest Cancer Res Treat. 2016;159:395–406.
- Dubard-Gault M. Breast cancer in women under 50 years old in Reunion between 2005 and 2010. Thesis of Medical Science 2013. In: Human Health and pathology [ dumas-00967404] 2014. https://dumas.ccsd.cnrs.fr/dumas-0096740. 2014. Assessed 11 Nov 2015. [French Document
- Ly M, Antoine M, André F, Callard P, Bernaudin JF, Diallo DA. Breast cancer in sub-Saharan African women: review. Bull Cancer. 2011;98:797–806.
- Ndamba Engbang JP, Essome H, Mve Koh V, Simo G, Sime Essam JD, Sone Mouelle A, et al. Breast cancer in Cameroon, epidemiological profile histo-epidemiological: about 3044 cases. Pan African Med J. 2015;21:7269.
- Edmund DM, Naaeder SB, Tettey Y, Gyasi RK. Breast cancer in Ghanaian women: what has changed? Am J Clin Pathol. 2013;140:97–102.
- Meye JF, Ngomo KM, Diallo I. Breast cancer hospital in Libreville. Méd Afr Noire. 2004;51:479–82.
- Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al.Personalizing the treatment of women with early breast cancer Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24:2206-23
- Gupta A, Jain J, Kumar A, Kumar S, Wadhwa N. Triple negative breast cancer – An overview and review of literature. Asian J Med Sci 2012;3:16-20.
- Desai SB, Moonim MT, Gill AK, Punia RS, Naresh KN, Chinoy RF, et al.Hormone receptor status of breast cancer in India: A study of 798 tumours. Breast 2000;9:267-70.
- Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE. Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S. – A SEER analysis. BMC Cancer 2010;10:191.
Corresponding Author
R.Elamyal
Surgical Oncology Department, National Cancer Institute, Misurata, LIBYA
DOI: https://dx.doi.org/10.18535/jmscr/v8i11.18
